Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all phasesBOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the formation of its Scientific Advisory Board (SAB) and inaugural appointment of Dr. Sara Hurvitz. “The formation of our SAB marks an important step ...